Quick Answer
ZEVRA THERAPEUTICS, INC. reported Cash And Cash Equivalents At Carrying Value of $62.41 million for the year ending 2025.
- ZEVRA THERAPEUTICS, INC. showed an increase of +84.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from ZEVRA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), ZEVRA THERAPEUTICS, INC.'s Cash And Cash Equivalents At Carrying Value has grown by 2,355.0%.
- Historical annual values: Fiscal year 2025: $62.41 million | Fiscal year 2024: $33.79 million | Fiscal year 2023: $43.05 million | Fiscal year 2022: $65.47 million | Fiscal year 2021: $112.35 million | Fiscal year 2020: $4.21 million | Fiscal year 2019: $3.22 million | Fiscal year 2018: $18.41 million | Fiscal year 2017: $10.87 million | Fiscal year 2016: $16.76 million | Fiscal year 2015: $32.32 million | Fiscal year 2014: $10.26 million | Fiscal year 2013: $1.97 million | Fiscal year 2012: $2.54 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: